The European Hematology Association Roadmap for European Hematology Research: a consensus document

Engert, A.; Balduini, C.; Brand, A.; Coiffier, B.; Cordonnier, C.; Dohner, H.; de Wit, T. D.; Eichinger, S.; Fibbe, W.; Green, T.; de Haas, F.; Iolascon, A.; Jaffredo, T.; Rodeghiero, F.; Salles, G.; Schuringa, J. J.; EHA, Roadmap for European Hematology Research (2016). The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica - the hematology journal, 101(2), pp. 115-208. Ferrata-Storti Foundation 10.3324/haematol.2015.136739

[img] Text
JKH_the EHA Roadmap for Europ. Hemat. Research_haematol.2015.136739.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Abstract The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at Euro 23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine sections in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients. Received December 15, 2015. Accepted January 27, 2016. Copyright © 2016, Ferrata Storti Foundation

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0390-6078

Publisher:

Ferrata-Storti Foundation

Language:

English

Submitter:

Jana Berger

Date Deposited:

24 Mar 2016 16:09

Last Modified:

16 Jun 2017 16:45

Publisher DOI:

10.3324/haematol.2015.136739

PubMed ID:

26819058

BORIS DOI:

10.7892/boris.79301

URI:

https://boris.unibe.ch/id/eprint/79301

Actions (login required)

Edit item Edit item
Provide Feedback